On April 6, 2025, the FDA published Eli Lilly’s clinical trial seeking approval for tirzepatide (Mounjaro) for use in people with type 1 diabetes who are overweight or living with obesity.
The clinical trial has not started recruiting yet.
This is exciting progress for the type 1 population.
As people with type 1 diabetes, there are actually 6 hormones we don’t produce properly. Insulin is the big one, of course. However, the beta cells that produce insulin normally communicate with other cells that regulate critical hormones affecting liver glucose production, appetite, rate of digestion (and impact of food on your blood sugar after eating), and more.
These medications have already demonstrated in off-label use to be hugely beneficial for T1D, but insurance providers and clinicians have it difficult for many to access these benefits.
Learn more:
- 1 Year on Ozempic: https://youtu.be/yC33hSHZ9hg
- Getting Ozempic with T1D: https://youtu.be/iEFywyNQcVU
- My First Month on Ozempic: https://youtu.be/YylFyOW-e1Q
Ginger Vieira has lived with type 1 diabetes since 1999 along with a few other chronic illnesses! She is the Cofounder of the Diabetes Nerd Network and the Diabetes Nerd Marketing agency. Ginger has authored hundreds of articles and several books, including Exercise with Type 1 Diabetes, Pregnancy with Type 1 Diabetes, Dealing with Diabetes Burnout, and Stop Overeating During Lows. Over her 20-year career (so far) in diabetes, she’s produced hundreds of articles and videos about life with diabetes. Her background includes a Bachelor of Science in professional writing and certifications in coaching, personal training, powerlifting, and Ashtanga yoga.